CompletedNCT00893841
Pramipexole added to quetiapine for depression in bipolarity
About this title
Read the official source — NCT00893841Medication studyAges 18–65United States + Canada
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- San Diego and 8 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateFebruary 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 96
- Sponsor
- Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00893841
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo Controlled Exploratory Study of Augmentation of Seroquel XR With Pramipexole Dihydrochloride for Bipolar Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
San Diego, United States · Kirkland, United States · Edmonton, Canada
6 more locations
- Penticton, Canada
- Vancouver, Canada
- Sydney, Canada
- London, Canada
- Montreal, Canada
- Québec, Canada
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.
Did this study involve medication?
Yes. The study involved medication, including quetiapine (Seroquel) XR, placebo and pramipexole dihydrochloride.
Who was this study for?
Listed age limits: 18 years to 65 years.
